First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival

... certain oncology indications. Reclast is contraindicated in patients with hypocalcemia (low blood calcium) and those who are allergic to zoledronic acid. Reclast ... by the prescriber prior to initiation of bisphosphonate treatment. hypocalcemia may occur with Reclast therapy. All patients with Paget's disease should ...

Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis

... certain oncology indications. Reclast is contraindicated in patients with hypocalcemia (low blood calcium) and those who are allergic to zoledronic acid. Reclast ... by the prescriber prior to initiation of bisphosphonate treatment. hypocalcemia may occur with Reclast therapy. In the Pivotal Fracture Trial an increased ...

New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis

... in patients with hypocalcemia, known hypersensitivity to any component of this product, or inability to stand or sit upright for at least 30 minutes. hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Actonel therapy. Actonel is not recommended for ...

ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

... cases, intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Once-yearly Reclast Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis

... osteoporosis. Reclast is contraindicated in patients with hypocalcemia (low blood calcium), hypersensitivity to zoledronic acid and in women who ... already being treated with Zometa should not be treated with Reclast. hypocalcemia may occur with Reclast therapy. All patients with Paget's disease should ...

Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO

... Grade 4 lymphopenia, neutropenia and thrombocytopenia were observed in 1, 2 and 2 patients, respectively. Grade 1-3 anemia, nausea/vomiting and hypocalcemia were observed in 18, 1, and 3 patients, respectively. “Myelosuppression, particularly neutropenia, is a substantial clinical problem in ...

Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...

Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer

... intravenous replacement was required. Patients receiving ERBITUX therapy should be periodically monitored for hypomagnesemia, and accompanying hypocalcemia and hypokalemia during, and up to 8 weeks following the completion of, ERBITUX therapy. The most serious adverse reactions associated with ERBITUX ...